CONGENITAL CARDIOLOGY TODAY

Timely News and Information for BC/BE Congenital/Structural Cardiologists and Surgeons

March 2014; Volume 12; Issue 3
International Edition

IN THIS ISSUE

CONGENITAL CARDIOLOGY TODAY
Editorial and Subscription Offices
16 Cove Rd, Ste. 200
Westerly, RI 02891 USA
www.CongenitalCardiologyToday.com

Upcoming Medical Meetings
(See website for additional meetings)

Masterclass in Cardiac Morphology - Living Anatomy
Mar. 14-15, 2014; Charleston, SC USA
clinicaldepartments.musc.edu/pediatrics/divisions/cardiology/cme_conferences

20th Annual Pediatric Echocardiography Conference: Screening, Diagnosing & Following the Patient with CHD
Mar. 21- 22, 2014; Atlanta, GA USA
www.choa.org/cmeevents

5th Phoenix Fetal Cardiology Symposium
Apr. 23-27, 2014; Phoenix, AZ USA
kpoole@phoenixchildrens.com

The 61st Annual Conference of the Isreal Heart Society in association with the Isreal Society of Cardiothoracic Surgery
Apr. 30-May1, 2014; Tel-Aviv, Israel
israelheart.com/

World Congress of Cardiology Scientific Sessions 2014
May 4-7, 2014; Melbourne, Australia
www.worldcardiocongress.org

Congenital Cardiology Today is The official publication of the CHiP Network (www.chipnetwork.org)

© 2014 by Congenital Cardiology Today ISSN: 1544-7787 (print); 1544-0499 (online). Published monthly. All rights reserved.

Angiotensin II Receptor Blocker Slows the Rate of Progression of Aortic Root Dilatation in Marfan Syndrome: Two Case Reports and Review of the Literature

By Huda Elshershari, MBBCh; Mosaab Esseid, MBBCh; Vithida Sueblinvong, MD; Catharine Harris, MD

Contributor's Statement

Huda Elshershari: Dr. Elshershari treated and followed the two cases, drafted the initial manuscript, and approved the final manuscript as submitted.

Mosaab Esseid: Dr. Esseid reviewed and revised the manuscript, and approved the final manuscript as submitted.

Vithida Sueblinvong: Dr. Sueblinvong treated and followed the two cases, reviewed and approved the final manuscript as submitted.

Catharine Harris: Dr. Harris carried out the initial genetic evaluation of both cases, critically reviewed the manuscript, and approved the final manuscript as submitted.

Abstract

Marfan Syndrome is a connective tissue disorder with significant cardiovascular complications such as aortic root dilatation, development of aortic aneurysm or rupture. We report two children diagnosed with Marfan Syndrome and aortic root dilatation in early childhood. Marfan Syndrome is caused by Fibrillin 1 gene mutation in both cases that was transmitted from affected parent. They were treated with Losartan which slowed the progression of aortic root enlargement.

Key Words: Marfan; Fibrillin; mutation; Losartan

Introduction

Marfan Syndrome is an autosomal dominant connective tissue disorder in which abnormalities occur in the cardiovascular, ocular and musculoskeletal systems. The majority of mutations occur in FBN1 gene located at chromosome 15q21.1.[1] However, 10% of the mutations occur in transforming growth factor-beta receptor 2 (TGFBR2) and 1 (TGFBR1) genes, respectively which result in Loeys-Dietz Syndrome (a connective tissue disorder with phenotypic overlap with Marfan Syndrome). The Fibrillin -1 is an important constituent of connective tissues, and the histopathology of aortic tissues shows fragmentation of elastic lamellae and fibrosis. The exact molecular mechanism is not understood, but one of the proposed mechanisms is increased bioavailability of transforming growth factor-beta (TGF-β). Recent research from mouse

CONGENITAL CARDIOLOGY TODAY

CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share?
Submit your manuscript to: RichardK@CCT.bz

NIT-OCCLUD®

COIL SYSTEM FOR PDA CLOSURE

A SAFER, EASIER WAY TO CLOSE

The Nit-Occlud® coil system for PDA closure is designed to match individual morphologies and sizes

The delivery system facilitates optimal device positioning

The Nit-Occlud® PDA coil is repositionable and retrievable prior to release

Tight and compact windings ensure efficient occlusion

The Nit-Occlud® PDA coil was determined to be MRI conditional

Radiopaque

For more information or to place an order, contact your B. Braun Interventional Systems Inc. representative or call 1-877-VENA-CAV (836-2228)

pfm medical

Manufacturer:
pfm medical, ag
Wankelstraße 60
50996 Köln, Germany
T +49 (0)2236 9641-10
F +49 (0)2236 9641-20

B|BRAUN Interventional Systems

Distributed by:
B. Braun Interventional Systems Inc.
824 Twelfth Avenue
Bethlehem, PA 18018 USA
Tel: 1-877-VENA CAV (836-2228) (USA)
Fax: 1-610-849-1334
www.bisusa.org

Indication: The Nit-Occlud® PDA coil is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter less than 4mm. Nit-Occlud Brief Statement: Do not implant the Nit-Occlud PDA into patients who have endocarditis, endarteritis, active infection, pulmonary hypertension (calculated PVR greater than 5 Wood Units), thrombus in a blood vessel through which access to the PDA must be obtained, thrombus in the vicinity of the implantation site at the time of the implantiton or patients with a body weight < 11 lbs (5 kg). An angiogram must be performed prior to implantation for measuring length and diameter of the PDA. Only the pfm medical implantation delivery catheter should be used to implant the device. Administration of 50 units of heparin per kg body weight should be injected after femoral sheaths are placed. Antibiotics should be given before (1 dose) and after implantation (2 doses) in order to prevent infection during the implant procedure. Do not implant the Nit-Occlud PDA in an MR environment. Do not pull the Nit-Occlud coil through heart valves or ventricular chambers. Contrast media should not be injected through the implantation catheter. The catheter must not be connected to high pressure injectors. Patients may have an allergic response to this device due to small amounts of nickel that has been shown to be released from the device in very small amounts. If the patient experiences allergic symptoms, such as difficulty in breathing or swelling of the face or throat, he/she should be instructed to seek medical assistance immediately. Antibiotic prophylaxis should be performed to prevent infective endocarditis during first 6 months after coil implantation. Potential Adverse Events: Air embolism, Allergic reaction to drug/contrast, Apnea, Arrhythmia requiring medical treatment or pacing, Arteriovenous fistula, Bacterial endocarditis, Blood loss requiring transfusion, Chest pain, Damage to the tricuspid or pulmonary valves, Death, Embolization of the occluder, requiring percutaneous or surgical intervention, Endarteritis, False aneurysm of the femoral artery, Fever,Headache/migraine, Heart failure, Hemolysis after implantation of the occluder, Hypertension, Hypotension or shock, Infection, Myocardial infarction, Occluder fracture or damage, Perforation of the heart or blood vessels, Stenosis of the left pulmonary artery or descending thoracic aorta, Stroke/TIA, Thromboembolism (cerebral or pulmonary), Valvular Regurgitation, Vessel damage at the site of groin puncture (loss of pulse, hematoma etc.)

models of Marfan Syndrome demonstrates aortic root enlargement due to excessive signaling by TGF-β.[2]

Angiotensin II Type 1 receptor blocker, Losartan (Cozaar, Merck) is a TGF-β antagonist, therefore, it prevents progressive enlargement of the aortic root.[2, 3] We present two cases of Marfan Syndrome with aortic root dilatation that were stabilized on Losartan treatment during early childhood.

Case 1

This male infant was born to a Hispanic family and the father had presumed diagnosis of Marfan Syndrome for many years, but had never been tested. He had a past history of aortic valve replacement and multiple eye surgeries. The mother and her other two children from a previous relationship were healthy. The infant was born at term by spontaneous vaginal delivery with a birth weight of 3200 gram (25th percentile) and a length of 51 cm (>50th percentile). Physical examination revealed long and protruding ears, micrognathia, high arched palate, arachnodactyly and undescended testicles. No heart murmur was heard. Ophthalmologic examination was unremarkable.

Initial echocardiogram study at one month of age showed aortic root dilatation measured 1.60 cm (Z = 2.94). The diagnosis of neonatal Marfan Syndrome was raised because of both physical findings and cardiac abnormality. Molecular genetic studies were performed for the infant and father which revealed a mutation in exon 31 of the FBN1 gene in the infant and his father. Losartan and propranolol therapies were initiated at three months of age. His blood pressure and renal function were closely monitored.

Case 2

A three-and-a-half-year old Hispanic male was referred for evaluation by an ophthalmologist because of visual examination failure at school; he was diagnosed with bilateral ectopia lentis; Marfan Syndrome was suspected, and was referred for genetic evaluation. Physical examination revealed tall stature (>95%), large ears, high arched palate and hyper-extensible elbows. No heart murmur was noticed. Further genetic testing confirmed mutation in exon 2 of the FBN1 gene in the child that was transmitted from his affected mother. Initial echocardiography was performed at 4 years of age showed aortic sinus dilatation and measured 2.45 cm (Z=2.37). Therefore, the patient was started on Losartan and Beta-blocker.

Treatment and Clinical Course

Both patients were started on Losartan (Cozaar, Merck) at an initial oral dose of 0.6 mg per kilogram per day. They were assessed for adverse events at this starting dose over a 3-week period before the dose was gradually increased to maximum 1.4 mg per kilogram per day. Blood pressure of both patients was closely monitored during follow-up after initiation of Losartan. The renal function (blood urea nitrogen and creatinine levels) and electrolyte levels were normal at initiation of therapy and after three months. The first case was continued on Beta-blocker therapy alone at one year of age, and Losartan was discontinued because of low blood pressure; his parents could not afford Losartan therapy. The second case was continued on Angiotensin receptor blocker medication alone; Beta-blocker was discontinued after 12 month of initiation of the combined therapy due to hypotension. Serial transthoracic echocardiogram examinations were performed to measure aortic sinus of Valsalva during follow-up visits for approximately 5 years.

"We present two cases of Marfan Syndrome with aortic root dilatation that was stabilized on Losartan treatment during early childhood."

Echocardiography Findings

Maximal aortic diameter was measured at the aortic annulus, sino-tubular junction, ascending thoracic aorta and aortic root (at the sinuses of Valsalva) in the parasternal long-axis view. All measurements were performed from internal edge to internal edge of the aortic wall during ventricular systole. Body mass index was calculated from height and weight, and were converted into Z score which is normalized for age and sex. Serial echocardiogram studies during follow-up for 5 years showed aortic root sinus dilatation with Z score above 3 in the first case; significant improvement of aortic root dilatation with Z score less than one in the second case as shown in the Table.

Discussion

Marfan Syndrome is a connective tissue disorder with significant cardiovascular complications such as aortic root dilatation, development of aortic aneurysm or rupture. The neonatal Marfan Syndrome presents with a rare and severe phenotype early in childhood. A severe or neonatal Marfan phenotype can be found with mutations in exons 24-27 and 31-32, and are thought to account for 20% of FBN1 mutations. These mutations are associated with more severe phenotype including earlier presentation, higher risk of scoliosis, ectopia lentis, ascending aorta dilatation, mitral valve abnormalities, and shorter survival.[1] We report on the clinical data of two boys diagnosed with Marfan Syndrome in early childhood that was transmitted from an affected parent. The first case was diagnosed during early infancy with the neonatal form of Marfan Syndrome, and the second case presented relatively later at 3 years of age because of vision problems.

Losartan is a new therapy, and used to slow the rate of aortic root dilatation in patients

Table: Serial Aortic Sinus Diameters

Case 1			Case 2		
Age‡ (M)	Aortic Sinus (cm)	Z Score	Age‡ (Y)	Aortic Sinus (cm)	Z Score
3	1.67*	3.40	4	2.45*	2.37
6	1.77†	3.39	4.5	2.55†	2.53
9	1.86†	3.40	4 y 10 m	2.63†	2.55
17	2.10††	3.98	5.5	2.54**	1.97
24	2.12	3.53	6	2.55	1.73
36	2.26	3.09	7	2.60	0.85
48	2.39	3.53	8	2.67	0.57
60	2.43	3.57	9	2.87	0.84

‡ Age M = month; Y = year
* Before Losartan therapy
† After initiation of losartan therapy and Beta-blocker
†† Patient is taking Beta-blocker alone
** Patient is taking Losartan alone
The Z scores were calculated from aortic-root diameters normalized for age and body-surface area with the use of standard algorithms.

with Marfan Syndrome. Losartan is antihypertensive agent and TGF-β antagonist with Angiotensin II Type 1 receptor blocker effect.[2, 3] Angiotensin II acts on Angiotensin II Type 1 and Angiotensin II Type 2 receptors, respectively.[3] The functions of Angiotensin II Type 1 and 2 receptors are mutually antagonist.[4]

Molecular studies described that TGF-β is an inactive latent complex, and requires bio-activation by Thrombospondin 1.[5] Zhou et al showed in their experimental study that Angiotensin II induces TGF-β activation by increasing Thrombospondin 1. Furthermore, Angiotensin II induction of Thrombospondin 1 and increased TGF-β activity were blocked by losartan.[6] Angiotensin II Type 1 receptor signaling is shown to increase TGF-β production. Habashi et al reported that aortic aneurysm in a mouse model of Marfan Syndrome is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists, the Angiotensin II Type 1 receptor blocker (Losartan). The authors concluded that β-adrenergic blockade with Propranolol diminished aortic growth rate in mice model of Marfan Syndrome, but did not prevent progressive deterioration of aortic wall architecture or aortic dilatation. Full correction of the aortic wall abnormalities in FBN1 mice model was achieved by Losartan via AT1 blockade effect.[7] Angiotensin II Type 1 receptor blocker (losartan) decreases TGF-β signaling, thus decreasing plasma TGF-β levels and over activation of Angiotensin II Type 2 receptor pathway.

Brooke et al. showed in a cohort study of 18 pediatric patients with Marfan Syndrome that Losartan slows the rate of progression of aortic root dilatation as compared to Beta-blocker alone.[8] A recent controlled trial on pediatric population comprised of 28 patients with Marfan Syndrome (Mean age 13 ± 6 years), 15 patients were randomized to receive Beta-blocker and Losartan, 13 patients received Beta-blocker alone. This study demonstrated that Losartan therapy is safe and more effective in slowing the progression of aortic root dilatation as compared to Beta-blocker therapy alone.[9] In another cohort study, twenty patients with Marfan Syndrome (aged 1.7 to 21.6 years) were enrolled in a prospective treatment study of Losartan for evaluation of the aortic dimensions.[10] The mean follow-up period was 33 ± 11 months. A significant reduction in the normalized aortic dimensions was observed with a better response to therapy when started at an earlier age and with a longer therapy duration.

Our observational study in two patients with Marfan Syndrome showed that Angiotensin II receptor blockers (Losartan) are beneficial in slowing the rate of progression of aortic root dilatation. Losartan therapy is more effective in slowing the progression of aortic root dilatation as demonstrated in the second case, compared to Beta-blocker therapy alone in the first case. Furthermore, our patients received the treatment at a younger age without any side effects. A double-blind, multicenter trial has been announced and will add to the knowledge of AT1-receptor blocker effects on aortic root dilatation in children with Marfan Syndrome.[11]

Conclusion

Losartan is currently in widespread clinical use for treatment of hypertension in both adults and children. Losartan is a TGF-β antagonist with Angiotensin II Type 1 receptor blocker effect which is a new therapy for stabilizing aortic root dilatation in Marfan Syndrome. This medication significantly slowed the progression of aortic enlargement in our patient without any side effects.

Financial Support: This brief report received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflict of Interest: None of the authors have any conflict of interest about the manuscript.

References

1. Pyeritz RE. Marfan syndrome and other disorders of fibrillin. In: Rimoin DL, Connor JM, Pyeritz RE, eds. Principles and Practice of Medical Genetics. 3rd ed. New York, NY: Churchill Livingstone Inc; 1997:1027-1066.
2. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Lariviere R. Neutralization of transforming growth factor - beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 2005;23:1895-903.
3. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12.
4. Horiuchi M, Akishita M, Dzan VJ. Recent progress in Angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-621.
5. Schultz- Cherry S, Murphy- Ullrich JE. Thrombospondin causes activation of latent transforming growth factor- beta secreted by endothelial cells by a novel mechanism. J Cell Biol 1993;122(4): 923-932.
6. Zhou Y, Poczatek MH, Berecek KH, Murphy- Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 2006;339:633-41.
7. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-21.
8. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz III HC. Angiotensin II blockade and Aortic –root dilatation in Marfans's syndrome. N Engl J Med 2008;358(26):2787-95.
9. Chiu HH, Wu MH, Wang JK, et al. Losartan Added to β-Blockade Therapy for Aortic Root Dilation in Marfan Syndrome: A Randomized, Open-Label Pilot Study. Mayo Clin Proc. 2013;88(3): 271-6.
10. Pees C, Laccone F, Hagl M, Debrauwer V, Moser E, Michel-Behnke I. Usefulness of Losartan on the Size of the Ascending Aorta in an Unselected Cohort of Children, Adolescents, and Young Adults With Marfan Syndrome. Am J Cardiol 2013 [Epub ahead of print].
11. Lacro RV, Guey LT, Dietz HC, et al. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J. 2013;165(5):828-835.

CCT

Corresponding Author

Huda Elshershari, MBBCh
Pediatric Cardiologist
University of New Mexico Children's Hospital
Children's Heart Center
2211 Lomas Blvd NE
Albuquerque, NM 87106 USA
Phone: 1 (505) 272-8780
Fax: 1 (505) 272-1212

Elshershari@hotmail.com

Mosaab Esseid, MBBCh
University of Colorado School of Medicine
Department of Pediatrics
Aurora, CO, USA

Vithida Sueblinvong, MD
University of Illinois College of Medicine
Department of Pediatrics
Chicago, IL, USA

Catharine Harris, MD
University of Missouri Health System
Department of Child Health
Columbia, MO, USA

Melody® Transcatheter Pulmonary Valve Ensemble® Transcatheter Valve Delivery System

Indications: The Melody TPV is indicated for use in a dysfunctional Right Ventricular outflow Tract (RVOT) conduit (≥16mm in diameter when originally implanted) that is either regurgitant (≥ moderate) or stenotic (mean RVOT gradient ≥ 35 mm Hg)

Contraindications: None known.

Warnings/Precautions/Side Effects:

- DO NOT implant in the aortic or mitral position.
- DO NOT use if patient's anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22-Fr size introducer, or if there is significant obstruction of the central veins.
- DO NOT use if there are clinical or biological signs of infection including active endocarditis.
- Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
- To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.
- The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.
- If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.

Potential procedural complications that may result from implantation of the Melody device include: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, and pain at the catheterization site.

Potential device-related adverse events that may occur following device implantation include: stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, and hemolysis.

For additional information, please refer to the Instructions for Use provided with the product or call Medtronic at 1-800-328-2518 and/or consult Medtronic's website at www.medtronic.com.

Humanitarian Device. Authorized by Federal law (USA) for use in patients with a regurgitant or stenotic Right Ventricular Outflow Tract (RVOT) conduit (≥16mm in diameter when originally implanted). The effectiveness of this system for this use has not been demonstrated.

Melody and Ensemble are trademarks of Medtronic, Inc.
UC201303735 EN © Medtronic, Inc. 2013;
All rights reserved.

PDA Closure in a Very Low-Weight Premature Infant with ADO II Device

By Jesús María Damsky Barbosa, MD; J. Alonso, MD; A. de Dios, MD

Introduction

Endovascular closure of Patent Ductus Arteriosus (PDA) is a procedure of choice.[1] More and more centers have started closing PDA in patients under 8 kg; PDA with substantial diameters are capable of producing severe heart failure and high morbidity in these patients. This situation is worse in prematures where PDA is of considerable diameters, large and tubular.[2]

Gregory Moore et al[3] suggest that PDA ligation is associated with an extended duration of mechanical ventilation and longer hospital stays in survivors, although mortality decreased over time.

The United Kingdom Surgical Central Cardiac Audit Database of children weighing <2.5 kg and undergoing surgery, demonstrates that ligation of the arterial conduits has an 8% mortality at 30 days for this group of patients, claiming that mortality would be associated with co-morbidities rather than with the surgical technique[4] and proposes to avoid thoracotomy as a co-morbidity factor.

Since April 2011, our group developed a PDA closure protocol[5] with the aim of reducing morbidity and which could be used in patients weighing <3 kg. PDA closure is achieved only by venous puncture, without arterial puncture and under strict echocardiography control. Thus, both the use of contrast and the fluoroscopy time were reduced, and potential arterial lesions, resulting from arterial puncture, were avoided.

After experience with 16 cases using this protocol in different ages and weights, we decided to start closing PDA in patients weighing <3 kg.

Case Report

A 26 week gestation preterm male patient with 15 days of chronological age, weighing 1,040 gr., required mechanical ventilation due to pulmonary edema and decompensate heart failure.

Transthoracic echocardiography showed the existence of a PDA with left chambers dilatation and moderate mitral valve regurgitation. Medical treatment with Indomethacin was soon started: two series were performed without favorable response, with persisting mitral valve regurgitation and significant left chambers dilatation. We proposed endovascular PDA closure.

In the cath lab, right femoral vein puncture was performed guided by echocardiography. The PDA was catheterized using a right coronary catheter 4 Fr, with the help of a Terumo 0.035" guide. Lateral view (see Figure 1) and right anterior oblique angiographies were executed.

PDA had the same diameter throughout the extension of 3.9 mm and 10 mm length.

We proceeded to occlude the PDA with an II 4-5 Amplatzer device (see Figure 2).

Transthoracic echocardiography control was then performed which ruled out left pulmonary artery stenosis or residual aortic coarctation (see Figure 3).

The total amount of nonionic contrast agent used was 6 cc, and the overall fluoroscopy time 7 minutes.



Figure 1. Lateral view: shows PDA and its measurements.



Figure 2. Lateral view: half-open left disk (red arrow) within the PDA and the right one (yellow arrow) absolutely unfolded in pulmonary artery.

Discussion

Endovascular PDA closure in very low-weight premature patients is a developing procedure. All of these patients are usually critical, under mechanical ventilation, hemodynamically decompensate, and, in general, had a previous medical treatment without favorable response. An Endovascular procedure is recommended to reduce postoperative morbidity.

To carry out this procedure,[5] it is required to know PDA's anatomy by transthoracic echocardiography, allowing us to decide which is the correct prosthesis for each case.[6] Arterial puncture should be avoided; accessing only by venous puncture reduces the use of contrast and decreases the fluoroscopy time to the most.



Picture 3: Shows the device correctly positioned in the right PDA (blue arrow) and absence of residual gradient in the left pulmonary artery (red arrow) and descending aorta (yellow arrow) from suprasternal view.

Different prostheses have been used to close PDA in premature infants: from coils[7] to[8] Amplatzer devices. In this case, we decided to use ADO II instead of ADO II AS, as recommended by Neil Wilson,[6] due to the disparate relation between the 3.9 mm diameter PDA and the 5 mm diameter Amplatzer, which caused concern about the possibility of embolization. This one being a large PDA, we decided to place an ADO II 5-4 (5 mm central body and 4 mm length with an 11 mm disk). The left disk was half-open in the PDA and the right one entirely open in the pulmonary artery without generating gradient on the left branch nor descending aorta. The result was excellent.

In the future, we hope to see the procedure carried out in the incubator, as Neil Wilson proposes.

This was the "first experience in Argentina."

Conclusion

- PDA closure was successfully achieved in a very low-weight premature infant.
- The procedure was done by venous vascular access.
- TTE helped in assessing the correct position of the device and ruled out residual aortic coarctation and left pulmonary stenosis.

References

1. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation 2006; 114:1873–1882.
2. Ewert P. Challenges encountered during closure of patent ductus arteriosus. Pediatr Cardiol 2005; 26: 224–229.
3. Gregory P Moore, Sarah L Lawrence, Gyaandeo Maharajh, Amanda Sumner, Isabelle Gaboury, Nick Barrowman, Brigitte Lemyre. Therapeutic strategies, including a high surgical ligation rate, for patent ductus arteriosus closure in extremely premature infants in a North American centre. Paediatr Child Health Vol 17 No 4 April 2012.
4. Cunningham D. NHS Information Authority.
5. Jesús Damsky Barbosa, Oscar Vagnola, Victorio Lucini, Adelia Marques Vitorino, Paula Manso, Judith Ackerman, Carolina Stepffer, Marina Vaccari, Fernanda Biancolini, Ana De Dios. Cierre de ductus por cateterismo con dispositivo Nit-Occlud®. Valor de la ecocardiografía transtorácica durante el cateterismo. Revista Argentina de Cardioangiología 2013;4(02):0099 -0107.
6. Philip Roberts, Satish Adwani, Nick Archer, Neil Wilson. Echocardiographically Guided Catheter Closure of Arterial Ducts in Small Preterm Infants on the Neonatal Intensive Care Unit. Catheterization and Cardiovascular Interventions 77:409–415 (2011).
7. Edwin Francis, DM, Anil Kumar Singhi, Srinivas Lakshmivenkateshaiah, Raman Krishna Kumar. Transcatheter Occlusion of Patent Ductus Arteriosus in Pre-Term Infants. JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 3, N° 5, MAY 2010: 550 – 5.
8. G Butera, G De Rosa, M Chessa, L Piazza, A Delogu, A Frigiola, M Carminati. Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children. Heart 2004;90: 1467–1470.

CCT

Corresponding Author

Jesús María Damsky Barbosa, MD
Chief of Hemodynamic Laboratory
"Pedro de Elilzade" Children Hospital
Buenos Aires, Argentina
Mobile: +54 9 11 5803-8203
jdamskyb@gmail.com

J. Alonso, MD
Hemodynamic Laboratory,
"Dr. Juan P. Garraham" Hospital
Buenos Aires, Argentina

A. de Dios, MD
Chief Unit of Cardiology
"Pedro de Elilzade" Children Hospital
Buenos Aires, Argentina

Archiving Working Group

International Society for Nomenclature of Paediatric and Congenital Heart Disease

ipccc-awg.net

Medical News, Products & Information

Edwards' SAPIEN XT Valve Approved in Europe for Transcatheter Mitral and Aortic Valve-in-Valve Procedures

(Marketwired) - Edwards Lifesciences Corporation, a global leader in the science of heart valves and hemodynamic monitoring, announced in February it has received CE Mark in Europe for valve-in-valve procedures using the SAPIEN XT transcatheter heart valve, providing a minimally invasive treatment option for patients whose surgical mitral or aortic valves require replacement, and who are at extreme risk for surgery. Edwards is the only company to receive a valve-in-valve indication for the mitral position, which addresses an unmet need within the clinical community to provide an alternative to a high-risk surgery.

"The European approval of the SAPIEN XT system for valve-in-valve procedures is a milestone achievement. While this is not a large financial opportunity, it represents an important benefit for patients unable to go through a second open-heart surgery to replace their failing bioprosthetic valves," said Larry L. Wood, Edwards' Corporate Vice President, transcatheter heart valves.

More than 300,000 valve replacements are performed worldwide each year through open-heart surgery, utilizing either bioprosthetic tissue valves or mechanical valves. Edwards' proven family of PERIMOUNT bovine pericardial tissue valves have been the world's most frequently implanted valves for more than 30 years, which surgeons have increasingly chosen over mechanical valves, even in younger patients. Patients who receive Edwards' bovine pericardial valves are generally not required to be on lifelong anticoagulation therapy (blood thinners), as they would if they had received a mechanical valve. Decades of clinical experience and peer-reviewed data on Edwards' valves provide robust evidence of long-term performance and optimal hemodynamics of the PERIMOUNT valve platform.

"Just as native heart valves experience wear over time, bioprosthetic valves eventually degenerate, too, creating a need for a replacement valve," said Olaf Wendler, MD, PhD, Professor of Cardiac Surgery, King's College Hospital in London, and one of the principal investigators of the SOURCE XT Registry. "The European adoption of valve-in-valve procedures using SAPIEN XT is an important development for treating patients who may otherwise go untreated. In particular, patients needing a re-operation to address a failing mitral valve face a very challenging surgery, and the ability to offer a transcatheter replacement is extremely important for this patient group." Dr. Wendler provides paid consulting services to Edwards for education, and research and development of transcatheter valve technologies.

In the U.S., the SAPIEN XT valve is not commercially available; it is an investigational device being studied as part of the randomized, pivotal PARTNER II Trial. For more information visit www.edwards.com.

Study Examines Effectiveness, Safety of Transcatheter Aortic Valve Replacement in US

Michael J. Mack, MD, of the Baylor Health Care System, Plano, Texas, and colleagues describe the experience in the U.S. with Transcatheter Aortic Valve Replacement (TAVR), including patient selection, procedural details, and in-hospital and 30-day outcomes following TAVR, a less invasive procedure than open heart-valve surgery for replacing the aortic valve in the heart.

In November 2011, the U.S. Food and Drug Administration (FDA) approved use of a valve that could be implanted using a catheter for TAVR for the treatment of severe, symptomatic aortic stenosis in patients with inoperable status. The label for the valve was expanded in September 2012 to include patients at "high-risk, but operable" status. Since commercial approval, this first-to-U.S.-market TAVR device has been introduced to nearly 250 U.S. clinical sites. "Although the [initial] trials demonstrated efficacy of TAVR within a select cohort of patients and hospital centers, there are no data on dissemination and utilization patterns of this technology in routine clinical practice in the United States. Additionally, concerns persist regarding the safety and effectiveness of this novel technology as it moves beyond protocolized trial care and highly experienced centers and operators," according to background information in the study.

For this study, the researchers gathered results from all eligible U.S. TAVR cases (n = 7,710) from 224 participating registry hospitals following the device commercialization (November 2011 - May 2013). Successful device implantation occurred in 7,069 patients (92%). In-hospital mortality was 5.5%. Other major complications included stroke (2.0%), dialysis-dependent renal failure (1.9%), and major vascular injury (6.4%).

Median hospital stay was 6 days, with 4,613 patients (63%) discharged home. Among patients with available follow-up at 30 days (n = 3,133), mortality was 7.6% (noncardiovascular cause, 52%); stroke occurred in 2.8%, and new dialysis in 2.5%.

"This analysis represents the first public report from the U.S. national Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, and documents two major findings. First, post-approval commercial introduction of this new technology with an early-generation device has yielded success rates and complication patterns that are similar to those documented in carefully performed randomized trials. Second, the outcomes of procedures even with this early-generation approved device are similar to the global experience of TAVR, which now is based on second- and third-generation improved devices. These findings help address a lingering question of clinical outcomes with the first-generation TAVR device after controlled U.S. dissemination to a relatively narrow group of treatment centers," the authors write. "Longer-term follow-up is essential to assess continued safety and efficacy as well as patient health status."

New Study Reports on the High Cost of Cardiac Surgery Healthcare Associated infections

Findings reported at *AHA Scientific Sessions 2013* reveal the economic impact of HAIs following cardiac surgery.

Western Society Of Pediatric Cardiology

25th Annual Conference of the
Western Society of Pediatric Cardiologists
Especially designed for care providers of patients with pediatric, adolescent, or adult congenital heart disease. Hosted by Children's Hospital of Orange County

April 11-13, 2014; St. Regis Monarch Beach, Dana Point, CA
www.choc.org/wsopc

CHOC Children's

JOIN US FOR THE 2014 ANNUAL INTERNATIONAL SYMPOSIUM FOR ADULT CONGENITAL HEART DISEASE.

Why?

BECAUSE YOUR PATIENTS TURN TO YOU AS THE **EXPERT IN CONGENITAL HEART DISEASE.**

EARLY REGISTRATION ENDS SOON!

JUNE 10-13, 2014

CINCINNATI, OHIO

SPACE IS LIMITED, PLEASE REGISTER TODAY BY VISITING

cincinnatichildrens.org/achdprogram

Cincinnati Children's®

Heart Institute

Discover the latest in adult congenital heart disease (ACHD) care and treatment during "Congenital Heart Disease in the Adult: An International Symposium." Continuing medical education credits will be awarded.

Pediatric and adult cardiovascular specialists and nurse practitioners worldwide are invited to learn about:

- Perioperative & critical care management
- Cardiac catheterization, including congenital & other structural interventions
- Exercise physiology, pathology & rehabilitation
- Electrophysiology: consensus guidelines for clinical management
- Pregnancy & heart disease
- Transitional medicine in congenital heart disease: concepts and practices

Presented by the Adolescent and Adult Congenital Heart Disease Program, part of the Heart Institute at Cincinnati Children's Hospital Medical Center.

Cincinnati Children's Hospital Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for *AMA PRA Category 1 Credit*™.

Contact hours will be awarded to nurses who attend the entire program and complete an evaluation tool. Cincinnati Children's Hospital (OH-046, 9/1/2015) is an approved provider of continuing nursing education by the Ohio Nurses Association (OBN-001-91), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

The study author is Giampaolo Greco, PhD, Assistant Professor of Health Evidence and Policy at Icahn School of Medicine at Mount Sinai.

After cardiac surgery, healthcare-associated infections (HAIs) are common complications associated with increased morbidity, mortality, and use of resources.

Study findings reported at the *American Heart Association's Scientific Sessions 2013* by investigators from the Cardiothoracic Surgical Trials Network (CTSN), whose Data and Clinical Coordinating Center is at Icahn School of Medicine at Mount Sinai, revealed the substantial economic impact of HAIs following cardiac surgery and the importance of preventing these infections leading to re-hospitalizations.

In the new analysis, researchers examined data about the incremental costs associated with major HAIs within 65 days of cardiac surgery. Clinical data from 4,320 patients at nine academic medical centers was merged with related financial data routinely collected by the University Health Consortium in the United States. The most common cardiac surgery procedures incurred by these patients included valve surgery, coronary artery bypass graft (CABG), and CABG/ valve surgery.

The data show during hospitalization, 2.7% of patients experienced major infections, such as pneumonia, sepsis, C. Difficile, and surgical site infections.

The average cost due to treating major HAI infection was calculated as about $40,000, with increased costs from Intensive Care Unit stays being an important contributing factor. Also, patients with major HAIs were nearly twice as likely to be readmitted as those with non-HAIs. In the patient population studied, there were 74 readmissions, with 8.7% due to HAIs.

"Our analysis found readmissions due to HAIs, after cardiac surgery cost on average nearly three times as much as non-HAI related readmissions," says Giampaolo Greco, PhD, Assistant Professor of Health Evidence and Policy at Icahn School of Medicine at Mount Sinai.

"We need to take action to avert preventable readmissions due to HAI infection rates after cardiac surgery, first for the patient's health and also to curb rising healthcare costs," says Dr. Greco.

This study was funded by the National Institutes of Health and Institute for Health Technology Studies (InHealth), a non-profit foundation.

As principal investigator for CTSN's Data and Clinical Coordinating Center based at Mount Sinai, Annetine C. Gelijns, PhD, Professor and Chair of the Department of Health Evidence and Policy at Icahn School of Medicine at Mount Sinai, previously received financial compensation as a consultant for InHealth's Research Council, which has supported some of the study-related analyses.

This study was presented at the *AHA Scientific Sessions 2013* in Abstract Poster Session (18267): The Economic Impact of Healthcare Associated Infections in Cardiac Surgery.

For more information, go to: www.mountsinai.org.

Heart Pump with Behind-the-Ear Power Connector: One-Third of Heart Failure Patients with Heart Pumps Develop Infection at Abdominal Power Connection Site

Newswise - Cardiac surgeons and cardiologists at the University of Maryland Heart Center are part of a multi-center clinical trial evaluating the efficacy of powering heart pumps through a skull-based connector behind the ear. Typically, these devices for patients with severe heart failure are energized through an electrical cord connected at an abdominal site, where potentially deadly infections can develop.

"Over time, nearly one-third of our patients surviving with the assistance of an implanted blood pump develop an infection at the site where the power cord exits the skin. This complication may be lethal but, if not, it is always a difficult problem," says the University of Maryland's principal investigator, Bartley P. Griffith, MD, The Thomas E. and Alice Marie Hales Distinguished Professor of Surgery at the University of Maryland School of Medicine, and a senior cardiac surgeon at the University of Maryland Medical Center.

Sponsored by

Phoenix Children's Hospital

Co-Hosted by

St. Joseph's Hospital and Medical Center
A Dignity Health Member

Dignity Health
Chandler Regional Medical Center

The Fifth

Phoenix Fetal Cardiology Symposium

April 23 through 27, 2014

The Ritz-Carlton
Phoenix, AZ 85016
www.fetalcardio.com







This conference offers the unparalleled exposure to national and international experts, creating an authoritative learning venue with an incredibly comprehensive and intensive program on fetal cardiology and fetal cardiology imaging. Lectures, procedure demonstrations and interactive case study formats will focus on expanding evidence-based care management strategies for clinical decision making.

This four-and-a-half day conference will:

- discuss important concepts in congenital heart disease as well as the most recent advances in imaging, diagnosis and management of fetal cardiac abnormalities.
- have added emphasis on the perinatal and genetics components, with advanced techniques in the assessment of the fetal circulation and extracardiac abnormalities
- have breakout workshops including 4D echo volume manipulation, hands on scanning, and Doppler assessment techniques are planned
- provide an opportunity for abstract submissions and poster presentations

Confirmed Guest Faculty Include:

Kathleen Bradley, MD
Jude Crino, MD
Bettina Cuneo,MD
Mary Donofrio, MD
Lisa Hornberger, MD
James Huhta, MD
Edgar Jaeggi, MD
Giancarlo Mari, MD
Anita Moon-Grady, MD
Jack Rychik, MD
Norman Silverman, MD
Wayne Tworetzky, MD

This symposium has been designed for physicians- both pediatric cardiology and maternal fetal medicine, sonographers and other paramedical colleagues. For more information regarding CME, please call (602) 933-0766.

For more information, email Kathryn Poole at kpoole@phoenixchildrens.com

The infection-prone abdominal connection also limits some activities such as swimming and bathing, since water may also contribute to infection.

The pumps, called Left Ventricular Assist Devices (LVADs), support the heart's main pumping chamber, the left ventricle. LVADs are implanted in the chest and powered with external batteries.

The study, named RELIVE (Randomized Evaluation of Long-term Intraventricular VAD Effectiveness), compares two similar continuous flow heart pumps designed for "destination therapy." The devices provide long-term support to patients with end-stage heart failure who, for a variety of reasons at the time of implant, are ineligible for a heart transplant. The major difference is in the way electrical power from the battery pack gets to each pump implanted in the chest. In one case, the internal power cord is routed through a traditional opening, or pump pocket, in the abdominal wall. In the other, the internal power cable is tunneled through the neck to the head. The internal cable is connected to a socket or pedestal placed behind the ear in the skull, in the same area used to pass cochlear implant electrode wires into the body. On the outside of the skull, a waterproof cable running from the battery pack is plugged into the socket.

Patients in the study are randomly assigned to one of two groups. The treatment group receives a Jarvik 2000 LVAD equipped with an investigational "post-auricular" connector from Jarvik Heart, Inc., the funder of the study. Control group patients are given a heart pump that employs an abdominal connector, Thoratec Corporation's HeartMate II Left Ventricular Assist System, which is the most widely used FDA-approved LVAD for destination therapy.

Part of the problem with the abdominal approach is related to the softness and flexibility of the abdomen. According to Dr. Griffith, tiny, micro-movements of the power cable at the abdominal entrance are all it takes to set the stage for infection. The investigators theorize that the stability of the bone-mounted terminal coupled with the vast blood supply in the scalp will reduce the chance of infection. "The bone in the skull is a better substrate to locate a foreign body on, because there's good blood flow, and there's no motion," says Dr. Griffith. At the same time, the investigators posit that the location of the connector in the head should provide quality of life benefits for patients who would otherwise not be able to take a shower or swim.

The cardiac team at the University of Maryland Heart Center has years of experience with both the HeartMate II and another version of the Jarvik 2000 with an abdominal pump pocket. Two other cardiac surgeons at the University of Maryland Medical Center are participating in the study: Keshava Rajagopal, MD, PhD, Assistant Professor of Surgery at the University of Maryland School of Medicine, and Si M. Pham, MD, Professor and Director of the Heart, Lung Transplant and Thoracic Mechanical Assist Devices Program at the University of Maryland School of Medicine. A cardiologist on the team, Erika D. Feller, MD, Assistant Professor at the University of Maryland School of Medicine and Medical Director of Heart Transplantation and Ventricular Assist Devices at the University of Maryland Medical Center, provides continuing cardiac care and monitoring of patients in the study.

Since the Jarvik implantation involves the head and neck, the cardiac team has formed an unusual collaboration with another surgical department at the School of Medicine. Ronna P. Hertzano, MD, PhD, Assistant Professor of Otorhinolaryngology-Head and Neck Surgery at the University of Maryland School of Medicine, extends the internal Jarvik power cord through the neck and places the socket in the skull. Dr. Hertzano, whose specialty includes hearing restoration and diseases of the ear and lateral skull base, works alongside the cardiac surgical team at the time of the procedure to correctly place the wire and skull connector.

"Cardiovascular disease kills one in three Americans. Particularly desperate is the plight of severely ill heart failure patients who have few options. The shortage of donor hearts for transplant has increased the need for functional and safe heart pump technology that not only keeps patients alive, but also extends the quality of their lives," says E. Albert Reece, MD, PhD, MBA, VP for Medical Affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine. "It is gratifying to see that School of Medicine faculty surgeons and cardiologists are at the forefront of research efforts that may

CONGENITAL CARDIOLOGY TODAY

CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share?

Submit your manuscript to:
RichardK@CCT.bz

- Title page should contain a brief title and full names of all authors, their professional degrees, and their institutional affiliations. The principal author should be identified as the first author. Contact information for the principal author including phone number, fax number, email address, and mailing address should be included.
- Optionally, a picture of the author(s) may be submitted.
- No abstract should be submitted.
- The main text of the article should be written in informal style using correct English. The final manuscript may be between 400-4,000 words, and contain pictures, graphs, charts and tables. Accepted manuscripts will be published within 1-3 months of receipt. Abbreviations which are commonplace in pediatric cardiology or in the lay literature may be used.
- Comprehensive references are not required. We recommend that you provide only the most important and relevant references using the standard format.
- Figures should be submitted separately as individual separate electronic files. Numbered figure captions should be included in the main Word file after the references. Captions should be brief.
- Only articles that have not been published previously will be considered for publication.
- Published articles become the property of the Congenital Cardiology Today and may not be published, copied or reproduced elsewhere without permission from Congenital Cardiology Today

FCS FETAL CARDIAC SYMPOSIUM 14 20

BASIC AND ADVANCED FETAL CARDIOLOGY SYMPOSIUM & WORKSHOP 2014

1ST ANNUAL MEETING
SAVE THE DATE JUNE 5-6, 2014; CHICAGO IL USA
http://fetalcardiacsymposium.com



Congenital Cardiology Today Can Help You Recruit:

- Pediatric Cardiologists
- pediatric Interventional Cardiologist
- Adult Cardiologist focused on CHD
- Congenital/Structural Heart Surgeons
- Echocardiographers, EPs
- Pediatric Transplant Cardiologist

Reach over 6,000 BC/BE Cardiologists focused on CHD worldwide:

- Recruitment ads include color!
- Issues's email blast will include your recruitment ad!
- We can create the advertisement for you at no extra charge!

Contact:
Tony Carlson
+1.301.279.2005 or tcarlsonmd@gmail.com

accomplish both goals. This research is part of our overall strategy to extend the best of care to our cardiac patients while also exploring more effective ways to prevent heart disease in the first place."

Infection was less of an issue in the early days of heart pump technology due to the limited durability of the devices, according to Dr. Rajagopal. "Device failure and many other problems associated with the early pumps, such as bleeding and clotting, limited patient survival. Infection was comparatively low on the list of concerns, but with more durable ventricular assist device therapies, infection is much more important than it was previously."

Early LVADs tried to mimic the normal heartbeat and its pulsating blood flow, circulating blood with a series of mechanical valves. They produced a pulse, but were prone to wear out quickly, and were used as a "bridge to transplant," a short-term life-saver until a donor heart could be found. Today, improved pump designs that produce continuous, minimally pulsatile blood flow make it possible for LVADs to run for years. Extended pump life, in turn, has been responsible for durable destination therapy, in which the device supports the patient for the remainder of his or her life.

The Jarvik skull model has already been approved for use in Europe. The clinical comparison study in the United States opened for patients this year. The University of Maryland enrolled the second patient in the U.S. to receive the Jarvik pump with the skull-based connector. The study will follow 350 patients for up to three years.

International Children's Heart Fund (ICHF) Looking for Volunteer Pediatric Interventionalists for Babyheart Missions in 2014

ICHF has conducted medical mission trips since the beginning of their work in 1993. Their trips have increased over the years so that now there are at least two ICHF Medical Teams every month repairing children's hearts somewhere in the world. The year 2013 represented their most ambitious schedule to-date. There are more trips on the schedule for 2014.

If you have what it takes to volunteer for a Babyheart Mission, contact Jean Towne, Medical Team Coordinator at jean.towne@babyheart.org.

The Mission Trip May-December 2014 Schedule is as follows:

- May 3 -17: Tegucigalpa, Honduras
- May 17 - 31: Kharkiv, Ukraine
- May 17 - 31: Guayaquil, Ecuador
- May 24 - Jun. 7: Jimani, Dominican Republic
- May 31 - Jun. 28: Benghazi, Libya Program
- May 31 - Jun. 14: Santiago, Dominican Republic
- May 31 - Jun. 14: Skopje, Macedonia
- Jun. 14-28: Kharkiv, Ukraine
- Jul. 12 - 26: Guayaquil, Ecuador
- Jul. 26 - Aug. 9: Santiago, DR
- Aug. 9 - 23: Enugu, Nigeria
- Sep. 6 - 20: Tegucigalpa, Honduras
- Sep. 6 - 20: Guayaquil, Ecuador
- Sep. 6 - 20: Kharkiv, Ukraine

International Children's Heart Foundation
Where Hope Comes to Life

Join Us for Two Weeks to Save Children with Congenital Heart Defects!

We are looking for medical volunteers who can join us in our missions to underdeveloped countries to perform pediatric cardiac surgery and care while also training the local medical staff.

For more information and our 2014 mission schedule, please visit Babyheart.org

- Sep. 13 - 27: Skopje, Macedonia
- Sep. 27 - October 11: Voronezh, Russia
- Oct. 25 - Nov. 8: Guayaquil, Ecuador
- Nov. 8 - 22: Tegucigalpa, Honduras
- Nov. 8 - 22: Santiago, Dominican Republic
- Nov. 8 - 22: Bishkek, Kyrgyzstan
- Nov. 22 - Dec. 6: Mirebalais, Haiti
- Dec. 6 - 20: Skopje, Macedonia
- December 6 - 20: Guayaquil, Ecuador

Radiation from Cardiology Procedures Equals More Than 50 Chest X-rays per Person Each Year

Cardiologists are being urged to reduce patient radiation exposure in a European Society of Cardiology (ESC) position paper which outlines doses and risks of common cardiology examinations for the first time. The paper was published in the *European Heart Journal,* January 9, 2014

Lead author, Dr Eugenio Picano, FESC, said, "Cardiologists today, are the true contemporary radiologists. Cardiology accounts for 40% of patient radiology exposure and equals more than 50 chest X-rays per person per year."

He added, "Unfortunately, radiation risks are not widely known to all cardiologists and patients and this creates a potential for unwanted damage that will appear as cancers, decades down the line. We need the entire cardiology community to be proactive in minimising the radiological friendly fire in our imaging labs."

The paper lists doses and risks of the most common cardiology examinations for the first time. Computed tomography (CT), percutaneous coronary intervention (PCI), cardiac electrophysiology and nuclear cardiology deliver a dose equivalent to 750 chest X-rays (with wide variation from 100 to 2,000 chest X-rays) per procedure. These procedures are performed daily in all cardiology in- and out-patient departments, usually more than one procedure per admission. They are used for all forms of cardiac disease, from congenital to heart failure, but more intensively and frequently for ischemic heart disease.

PCI for dilation of coronary artery stenosis totals almost 1 million procedures per year in Europe. The additional lifetime risk of fatal and non-fatal cancer for one PCI ranges from 1 in 1000, to 1 in 100 for a healthy 50 year old man. Risks are 1.38 times higher in women and 4 times higher in children. Children's higher risk is because their cells divide more quickly and they have more years in which to develop cancer.

Dr Picano said, "Even in the best centres, and even when the income of doctors is not related to number of examinations performed, 30 to 50% of examinations are totally or partially inappropriate according to specialty recommendations. When examinations are appropriate, the dose is often not systematically audited and therefore not optimised, with values which are 2 to 10 times higher than the reference, expected dose."

The paper aims to reduce the unacceptably high rate of inappropriate examinations and reduce excessive doses in appropriate examinations. Dr Picano said: "In these hard economic times, 50% of the costly and risky advanced imaging examinations we do are for inappropriate indications. Politicians' top priority should be to audit and cut down on useless and dangerous examinations."

He added, "Decreased doses can best be accomplished by working with industry and many companies are now successfully fighting a 'dose war'. Companies who develop better ways of reducing doses will win in the future global competition. Radiological sustainability is becoming a competitive marketing advantage."

The paper says that patients should be given the estimated dose before a procedure and the actual dose in writing afterwards if they request it. This could become a legal requirement through the European Directive Euratom law 97/43, but application of the law is being delayed by technical and practical difficulties.

Dr Picano said, "Patients can protect themselves by not self-prescribing screening examinations promoted by irresponsible advertisers. Second, before any testing they should ask their doctor what is the likely radiation dose they will get from that examination. After the exam they should receive the true delivered dose in a written report, which may differ by a factor of 10 from the theoretical reference dose."

He added, "The smart patient, and the smart cardiologist, cannot be afraid of radiation since it is essential and often life saving. But they must be very afraid of radiation negligence or unawareness. This paper will help to make cardiology wards and laboratories a safer place for patients and doctors through an increase of radiation awareness and knowledge."

Professor Patrizio Lancellotti, FESC, President of the European Association of Cardiovascular Imaging (EACVI) of the ESC, said, "The radiation issue was first brought to the attention of the international cardiology community by European cardiologists and now it is right and fitting that the ESC delivers this paper."

Heart Attack Damage Slashed with Microparticle Therapy - First Therapy to Target Damage after Heart Attack Could Transform Field

After a heart attack, much of the damage to the heart muscle is caused by inflammatory cells that rush to the scene of the oxygen-starved tissue. But that inflammatory damage is slashed in half when microparticles are injected into the blood stream within 24 hours of the attack, according to new preclinical research from Northwestern Medicine® and the University of Sydney in Australia.

When biodegradable microparticles were injected after a heart attack, the size of the heart lesion was reduced by 50% and the heart could pump significantly more blood.

"This is the first therapy that specifically targets a key driver of the damage that occurs after a heart attack," said investigator Daniel Getts, a visiting scholar in microbiology-immunology at Northwestern University Feinberg School of Medicine. "There is no other therapy on the horizon that can do this. It has the potential to transform the way heart attacks and cardiovascular disease are treated."

The micoparticles work by binding to the damaging cells -- inflammatory monocytes -- and diverting them to a fatal detour. Instead of racing to the heart, the cells head to the spleen and die.

The particles are made of poly (lactic-co-glycolic) acid, a biocompatible and biodegradable substance already approved by the Food and Drug Administration (FDA) for use in re-absorbable sutures. A microparticle is 500 nanometers, which is 1/200th size of a hair.

The scientists' study showed the microparticles reduced damage and repaired tissue in many other inflammatory diseases. These include models of West Nile virus, colitis, inflammatory bowel disease, multiple sclerosis, peritonitis and a model that mimics blood flow after a kidney transplant.

"The potential for treating many different diseases is tremendous," said investigator Stephen Miller, the Judy Gugenheim Research Professor at Feinberg. "In all these disease models, the microparticles stop the flood of inflammatory cells at the site of the tissue damage, so the damage is greatly limited and tissues can regenerate."

Getts, Miller and Nicholas King, Professor of Viral Immunopathology at the University of Sydney School of Medical Sciences, are corresponding authors on the paper, which was published January 15th in *Science Translational Medicine.*

Biotech Startup Aims for FDA Approval and Clinical Trial

The Northwestern and University of Sydney results are so encouraging, the scientists have partnered with a startup biotechnology company, Cour Pharmaceutical Development Co., to produce a refined version of the microparticles in anticipation of what they hope will be a clinical trial in myocardial infarction (heart attack) within two years. The company plans to submit an investigational new drug application to the FDA.

"This discovery has the potential to transform how inflammatory disorders are treated and the use of microparticles derived from biodegradable polymers means that this therapy could be rapidly translated for clinical use," said John Puisis, the Chief Executive Officer of Cour.

How a Fatal Attraction Saves the Heart

The microparticles are designed to have a negative charge on their surface. This makes them irresistible to the inflammatory monocytes, which have a positively charged receptor. It's a fatal attraction. When the inflammatory cell bonds to the microparticle, a signal on the cell is activated that announces it's dying and ready for disposal. The cell then travels to the spleen, the natural path for the removal of dying cells, rather than going to the site of the inflammation.

"We're very excited," King said. "The potential for this simple approach is quite extraordinary. Inflammatory cells pick up immune-modifying microparticles and are diverted down a natural pathway used by the body to dispose of old cells.

It's amazing that such a simple detour limits major tissue damage in such a wide range of diseases."

The research was supported by grants NS-026543 from the National Institute of Neurological Diseases and Stroke and EB-013198 from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health, and the National Health and Medical Research Council in Australia.

Getts and Miller have an interest in Cour Pharmaceutical Development Co. Getts is the Chief Scientific Officer.

CONGENITAL CARDIOLOGY TODAY

CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share?
Submit your manuscript to:
RichardK@CCT.bz

CONGENITAL CARDIOLOGY TODAY

© 2014 by Congenital Cardiology Today (ISSN 1554-7787-print; ISSN 1554-0499-online). *Published monthly. All rights reserved.*

Publication Headquarters:
8100 Leaward Way, Nehalem, OR 97131 USA

Mailing Address:
PO Box 444, Manzanita, OR 97130 USA
Tel: +1.301.279.2005; Fax: +1.240.465.0692

Editorial and Subscription Offices:
16 Cove Rd, Ste. 200, Westerly, RI 02891 USA

www.CongenitalCardiologyToday.com

Publishing Management:
- Tony Carlson, Founder, President & Sr. Editor - *TCarlsonmd@gmail.com*
- Richard Koulbanis, Group Publisher & Editor-in-Chief - *RichardK@CCT.bz*
- John W. Moore, MD, MPH, Group Medical Editor - *JMoore@RCHSD.org*
- Virginia Dematatis, Assistant Editor
- Caryl Cornell, Assistant Editor
- Loraine Watts, Assistant Editor
- Chris Carlson, Web Manager
- William Flanagan, Strategic Analyst
- Rob Hudgins, Designer/Special Projects

Editorial Board: Teiji Akagi, MD; Zohair Al Halees, MD; Mazeni Alwi, MD; Felix Berger, MD; Fadi Bitar, MD; Jacek Bialkowski, MD; Mario Carminati, MD; Anthony C. Chang, MD, MBA; John P. Cheatham, MD; Bharat Dalvi, MD, MBBS, DM; Horacio Faella, MD; Yun-Ching Fu, MD; Felipe Heusser, MD; Ziyad M. Hijazi, MD, MPH; Ralf Holzer, MD; Marshall Jacobs, MD; R. Krishna Kumar, MD, DM, MBBS; John Lamberti, MD; Gerald Ross Marx, MD; Tarek S. Momenah, MBBS, DCH; Toshio Nakanishi, MD, PhD; Carlos A. C. Pedra, MD; Daniel Penny, MD, PhD; James C. Perry, MD; P. Syamasundar Rao, MD; Shakeel A. Qureshi, MD; Andrew Redington, MD; Carlos E. Ruiz, MD, PhD; Girish S. Shirali, MD; Horst Sievert, MD; Hideshi Tomita, MD; Gil Wernovsky, MD; Zhuoming Xu, MD, PhD; William C. L. Yip, MD; Carlos Zabal, MD

Statements or opinions expressed in Congenital Cardiology Today reflect the views of the authors and sponsors, and are not necessarily the views of Congenital Cardiology Today.

Global Heart Network Foundation
It Takes Heart To Care For Hearts

Global Heart Network Foundation (GHN)
a global non-profit organization with a mission to connect people and organizations focused on the delivery of cardiovascular care across the Globe to increase access to care.
Contact: annabel@globalheartnetwork.net

www.globalheartnetwork.net

TOSHIBA
Leading Innovation

TINY HEARTS **inspired**

HYBRID LABS WITH ACCESS FOR BIG TEAMS.

Fixing a heart from birth through adulthood takes big teams working together. So we examined the needs of leading clinicians when designing our hybrid solutions. The result: our Infinix™-i with 5-axis positioners and low profile detectors, stays out of the way, but right where needed, providing the best possible access to patients. To lead, you must first listen. ***medical.toshiba.com***

youtube.com/toshibamedical @ToshibaMedical